Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Other financing activities (2018 - 2025)

Harvard Bioscience (HBIO) has disclosed Other financing activities for 10 consecutive years, with $24000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other financing activities changed N/A to $24000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $201000.0, a 151.28% increase, with the full-year FY2024 number at $161000.0, changed N/A from a year prior.
  • Other financing activities was $24000.0 for Q3 2025 at Harvard Bioscience, down from $75000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $2.6 million in Q3 2021 to a low of -$451000.0 in Q4 2023.
  • A 5-year average of $350071.4 and a median of $129000.0 in 2023 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: soared 27800.0% in 2022, then tumbled 197.83% in 2023.
  • Harvard Bioscience's Other financing activities stood at $861000.0 in 2021, then crashed by 46.46% to $461000.0 in 2022, then crashed by 197.83% to -$451000.0 in 2023, then surged by 122.62% to $102000.0 in 2024, then crashed by 76.47% to $24000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Other financing activities are $24000.0 (Q3 2025), $75000.0 (Q1 2025), and $102000.0 (Q4 2024).